Skip to content

AUSTRALIA

Our Board of Directors

Our Board Members include Founding Members Giovi and Charles Moschoudis, parents to Angelina who has CASK Gene Disorder. 

Each of our board members volunteer and dedicate their time to this extraordinary cause.

Giovi Moschoudis

Chief Executive Officer

Dr Charles Moschoudis

Director

Screenshot_22

Karina Davis

Director

Anthony Moschoudis

Secretary

Giovi Moschoudis

Chief Executive Officer

Giovi resigned from her professional career as a lawyer in 2019 to become a full time carer for Angelina and commit to her daily intensive therapies and medical appointments. 

Giovi was admitted as a Legal Practitioner of the Supreme Court of NSW during the early 2000’s, taking a practising certificate as a Solicitor. Her key strengths include strong planning, analytical and problem-solving skills, excellent interpersonal, verbal and written communication skills, and high attention to detail. 

Giovi hopes that these skills will assist in building this Foundation as she has a personal appreciation of CASK and the significant impact it has not only on the patient, but also their family.

Dr Charles Moschoudis

Director

Charles is Angelina’s father. 

He has over two decades of experience in the provision of leadership, guidance, and advice at senior levels in both the public and private sector. 

Dr Moschoudis is an Adjunct Professor at Torrens University Australia (AGSL).

Karina Davis

Director

Karina has completed a Bachelor of Education at the Australian Catholic University and Masters of Education Leadership at Macquarie University.
Karina has highly developed interpersonal skills and works closely with committed and skilled professionals.
During Karina’s teaching experience, she has been heavily involved in data analysis and leadership responsibilities.
Karina is currently the co-ordinator and leads a team who provide learning support for children who have special needs.

Anthony Moschoudis

Secretary

Anthony Moschoudis is a Senior Executive in the financial sector.

He has considerable experience in the private sector in the context of corporate leadership, having taken on various board appointments.

He has a wealth of strategic and operational experience relevant to corporate governance and management.

“In some ways, that CASK-linked pathology is degenerative in nature provides a positive outlook. Because microcephaly in CASK-linked pathology progresses postnatally, there may be a temporal window when therapeutic intervention might prevent or slow further brain cell loss. Regression, even in adolescence, has also been observed in some cases of MICPCH [119], again offering the tantalizing possibility that a therapeutic approach might prevent such decline under conditions when degeneration is known to progressThe potential benefits of intervention might extend even further given that non-cell-autonomous toxicity could also affect functioning of the remaining neurons; reduction of such toxicity, especially when coupled with high-intensity rehabilitative measures [120], might offer real hope for a positive impact on functional outcomes.”   

https://www.mdpi.com/2073-4409/11/7/1131/htm